|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Evidence that the angiotensin-converting enzyme inhibitors have important effects on cell growth, as well as on vascular tone, suggests that their ability to prolong survival in patients with heart failure may be due largely to the inhibition of detrimental effects of angiotensin II on cardiac gene expression.
|
1414889 |
1992 |
|
Heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
First, we investigated the gene expression of ACE in human heart failure.
|
7713116 |
1994 |
|
Heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Thus, the expression of the cardiac ACE but not of human heart chymase is upregulated in failing human heart indicating an activation of the cardiac renin-angiotensin system in patients with advanced heart failure.
|
8040271 |
1994 |
|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Angiotensin-converting enzyme gene DD polymorphism was associated with poorer survival and an increase in left ventricular mass in patients with idiopathic heart failure.
|
8752809 |
1996 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Possibly the single most important observation in clinical cardiovascular medicine in 1995 was the reporting of a highly significant interaction between angiotensin-converting enzyme inhibitors and aspirin on mortality in patients with ventricular dysfunction with or without heart failure.
|
8835867 |
1996 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
The great variety of cardiovascular effects mediated by these vasoactive peptides and the efficacy of ACE inhibitors in the treatment of hypertension and heart failure emphasize the prominent role of ACE in the cardiovascular system.
|
9428619 |
1998 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
1.The crucial role played by the renin-angiotensin-aldosterone system in the cardiovascular system and the immense therapeutic potential of angiotensin-converting enzyme inhibitors and, more recently, angiotensin II receptor blocking agents, in both heart failure and post-myocardial infarction is becoming increasingly evident.
|
9486084 |
1997 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Whereas the results are not conclusive, there may be a significant interaction between ACE genotype and response to ACE inhibitors in patients with heart failure.
|
9869506 |
1998 |
|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Does angiotensin-converting enzyme polymorphism influence the clinical manifestation and progression of heart failure in patients with dilated cardiomyopathy?
|
10072245 |
1999 |
|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The ACE genotype was determined in 171 patients selected with IDC in New York Heart Association functional class II to III heart failure and with a LV ejection fraction of < or = 40%.
|
10080429 |
1999 |
|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
An association between the DD allele of the angiotensin-converting enzyme gene and a poorer outcome in patients with heart failure has been found in whites.
|
10097225 |
1999 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
GH effects were examined at early (4 months) and late (10 months) phases of disease in the cardiomyopathic (CM) hamster, and the combination of GH with chronic ACE inhibition was assessed in late-phase heart failure.
|
10525494 |
1999 |
|
Heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
We analyzed whether angiotensin-converting enzyme (ACE) mRNA expression in heart failure is altered in the atrial myocardium, and whether a correlation exists between atrial ACE mRNA expression and the parameters of left ventricular function.
|
10619441 |
1999 |
|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Preliminary studies suggest that the I/D polymorphism of the Angiotensin Converting Enzyme gene influence the development of left ventricular hypertrophy, a major determinant of heart failure.
|
10937920 |
1999 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
ACE2, the first known human homologue of angiotensin-converting enzyme (ACE), was identified from 5' sequencing of a human heart failure ventricle cDNA library.
|
10969042 |
2000 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
These findings might explain the remarkable benefits of ACE inhibition in the treatment of heart failure.
|
11168675 |
2000 |
|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
These findings suggest a potential pharmacogenetic interaction between the ACE D/I polymorphism and therapy with beta-blockers in the determination of heart failure survival.
|
11273991 |
2001 |
|
Heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, an up-regulation of myocardial ACE gene expression has been observed in patients with heart failure.
|
11985486 |
2002 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
ACE inhibitors are recognised as being highly effective therapy for hypertension and cardiac insufficiency, and have a more beneficial effect on survival rate than expected on the basis of known mechanisms of action.
|
12076180 |
2002 |
|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Angiotensin-converting enzyme genotype modulates pulmonary function and exercise capacity in treated patients with congestive stable heart failure.
|
12356632 |
2002 |
|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Angiotensin-converting enzyme-deletion (DD) polymorphism has been shown to influence beta-blocker therapy in heart failure.
|
12476935 |
2002 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Modulation of the renin-angiotensin system, particularly inhibition of the angiotensin-converting enzyme (ACE), has become a prime strategy in the treatment of hypertension and heart failure.
|
12700890 |
2003 |
|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
No evidence was found to support an association between ACE genotype and HF.
|
14602526 |
2004 |
|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
LHGDN |
Effects of ACE gene insertion/deletion polymorphism on response to spironolactone in patients with chronic heart failure.
|
15121491 |
2004 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Since genetic polymorphisms affecting drug metabolizing enzymes or drug receptors are known to influence responses to drugs, exploration of these effects on treatment responses to ARBs and ACE inhibitors may provide for more targeted treatment of HF.
|
15320851 |
2003 |